Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERANCE trial in elderly patients with advanced soft tissue sarcoma
NL-OMON51478Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, cyclophosphamide, prednisolone and prednisone in soft tissue sarcoma (STS) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Difference in physical functioning at 12 weeks and Difference in role functioning at 12 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
doxorubicincyclophosphamideprednisoloneprednisone
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON51478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51478.